



# Think Sancuso® First

**1** PATCH > **5** DAYS Prevention of CINV<sup>\*1,2</sup>

Preventing.....



**SANCUSO® is recommended in the National Comprehensive Cancer Network (NCCN) antiemetic treatment guidelines for the prevention of CINV<sup>4</sup>**

The use of SANCUSO® complies with the NCCN recommendation that choice of antiemetic is based on the emetogenicity of the chemotherapy regimen and individual patient factors (eg, partial or complete bowel obstruction, concomitant drug treatments, including opiates)<sup>4</sup>

\* CINV (chemotherapy-induced nausea and vomiting)

Abbreviated Package Insert of SANCUSO® Transdermal system 3.1mg/24hours

Composition: Granisetron. Indication: Prevention of nausea & vomiting in patients receiving moderately &/or highly emetogenic chemotherapy of up to 5 consecutive days. Dosage & Administration: Adult Apply a single patch to the upper outer arm for a min of 24 hr before chemotherapy. May be applied to a max of 48 hr before chemotherapy as appropriate. Remove the patch a min of 24 hr after completion of chemotherapy. Can be worn for up to 7 days depending on the duration of the chemotherapy regimen. Contraindications: Hypersensitivity. Precautions: May mask a progressive ileus &/or gastric distention. Serotonin syndrome is associated with the use of the patch, particularly with concomitant use of serotonergic drugs. Remove patch if severe reactions or a generalized skin reaction occur. Avoid exposing the patch and surrounding area to direct external heat sources, such as heating pads. Avoid direct exposure of application site to natural or artificial sunlight. Pregnancy & lactation; Children; Elderly. Common adverse reactions: Constipation, headache. Interaction: Serotonin syndrome may occur following the concomitant use of 5-HT3 receptor antagonists & other serotonergic drugs. P/P: Transdermal patch 34.3 mg/52 cm<sup>2</sup> x 1's. Approved version of package insert: Jan 2017

Please refer to the full prescribing information before prescribing. Further information is available upon request.

Reference: 1. Hong Kong Prescribing information, Jan 2017. 2. Boccia, R.V., Gordan, L.N., Clark, G., Howell, J.D., Grunberg, S.M.; Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011; 19: 1609-17. 3. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2008/022198\\_sancuso\\_toc.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022198_sancuso_toc.cfm). 4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis. Version 2.2020.

**Kyowa KIRIN**

Kyowa Kirin Hong Kong Co., Ltd.  
Unit B, 13/F, 169 Electric Road, North Point, Hong Kong  
Tel: (852) 2956 0828 Fax: (852) 2956 1627  
[www.kyowa-kirin.com/hk](http://www.kyowa-kirin.com/hk)

KXHK-SAN-04-FEB2021